BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29500545)

  • 1. Effect of Qinghuang Powder () Combined with Bupi Yishen Decoction () in Treating Patients with Refractory Cytopenia with Multilineage Dysplasia through Regulating DNA Methylation.
    Zhou QB; Yang XH; Wang HZ; Wang DX; Xu YG; Hu XM; Xu FQ; Ma R
    Chin J Integr Med; 2019 May; 25(5):354-359. PubMed ID: 29500545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder.
    Xu S; Ma R; Hu XM; Xu YG; Yang XH; Wang HZ; Sun SZ; Liu F
    Chin J Integr Med; 2011 Nov; 17(11):834-9. PubMed ID: 22057412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of treatment for hypocellular myelodysplastic syndromes by a low dose qinghuang powder combined with Chinese drugs for Shen supplementing and Pi invigorating: a clinical observation].
    Zhou QB; Wang HZ; Gao F; Tang XD; Xu S; Yang XH; Xu YG; Hu XM; Ma R
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Dec; 34(12):1444-8. PubMed ID: 25632743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder () in Patients with Myelodysplastic Syndrome.
    Deng ZY; Zhu SR; Wang MJ; Fang S; Zhao P; Zhu QZ; Wang HZ; Guo XQ; Xu YG; Yi BW; Shang XH; Ma R; Hu XM
    Chin J Integr Med; 2019 Jul; 25(7):497-501. PubMed ID: 31278627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of Qinghuang Powder combined Chinese herbs for Pi-strengthening and Shen-reinforcing on HIF-1alpha in bone marrow mononuclear cells of myelodysplastic syndrome patients: an experimental research].
    Gao F; Xu YG; Yang XH; Ma R
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Feb; 34(2):174-8. PubMed ID: 24672941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Arsenic-Containing Qinghuang Powder: A Potential Drug for Myelodysplastic Syndromes.
    Ming J; Liu WY; Xiao HY; Xu YG; Ma R; Hu XM
    Chin J Integr Med; 2022 Aug; 28(8):762-768. PubMed ID: 32146594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of treatment for myelodysplastic syndrome by Qinghuang Powder combined with Chinese herbs for reinforcing shen and strenghening pi].
    Xu S; Hu XM; Xu YG
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Mar; 28(3):216-8. PubMed ID: 18476419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic-Containing Qinghuang Powder () is an Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy.
    Fan T; Quan RC; Liu WY; Xiao HY; Tang XD; Liu C; Li L; Lv Y; Wang HZ; Xu YG; Guo XQ; Hu XM
    Chin J Integr Med; 2020 May; 26(5):339-344. PubMed ID: 31848890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of myelodysplastic syndrome by hematopoietic stem cell transplantation combined with Chinese medical syndrome typing: a clinical study].
    Zhang Y; Ye BD; Qian LL; Gao YT; Wen XW; Shen JP; Zhou YH
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jan; 35(1):53-6. PubMed ID: 25790675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
    Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
    Wang H; Wang XQ; Xu XP; Lin GW
    Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
    Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome.
    Cermák J; Michalová K; Brezinová J; Zemanová Z
    Leuk Res; 2003 Mar; 27(3):221-9. PubMed ID: 12537974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder () in Patients with Myelodysplastic Syndromes.
    Zhao P; Liang JB; Deng ZY; Wang MJ; Qin JY; Chen CJ; Hu XM
    Chin J Integr Med; 2019 Jun; 25(6):409-415. PubMed ID: 29619748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of qinghuang power combined Chinese herbs for shen reinforcing and Pi strengthening on activated T cells of myelodysplastic syndrome patients].
    Gao F; Ma R; Yang XH; Xu YG
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Apr; 33(4):443-7. PubMed ID: 23841258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of genes underlying different methylation profiles in refractory anemia with excess blast and refractory cytopenia with multilineage dysplasia in myelodysplastic syndrome.
    Lee S; Kwon HC; Kim SH; Oh SY; Lee JH; Lee YS; Seo D; Han JY; Kim HJ
    Korean J Hematol; 2012 Sep; 47(3):186-93. PubMed ID: 23071473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
    Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
    Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study.
    Xiao Z; Xu Z; Zhang Y; Qin T; Zhang H; Fang L
    Leuk Res; 2011 Jan; 35(1):61-5. PubMed ID: 20591481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.